Legend Biotech (LEGN) CEO Exit Tests Management Stability Around Its CAR-T Multiple Myeloma Strategy

• Legend Biotech recently announced that Ying Huang, Ph.D., has stepped down as Chief Executive Officer and Board member, effective July 24, 2026, with CARVYKTI business unit President Alan Bash appointed as Interim CEO and Dr. Huang staying on briefly as an advisor.

• This leadership reshuffle at the top of a company built around a single, high-profile CAR-T franchise raises important questions about continuity in execution, partnerships, and global expansion plans.

• Now we’ll examine how the sudden CEO resignation and interim appointment could influence Legend Biotech’s multiple myeloma-focused investment narrative.

Rare earth metals are the new gold rush. Find out which 29 stocks are leading the charge.

Legend Biotech Investment Narrative Recap

To own Legend Biotech, you need to believe that CARVYKTI can support a focused, high-cost cell therapy business long enough for the broader pipeline to matter. The sudden CEO change introduces extra uncertainty around execution, but with CARVYKTI’s business unit head stepping in as interim CEO, the immediate impact on the key near term catalyst and the main product concentration risk does not yet look structurally different.

The recent US$225.995 million follow on equity offering in June 2026 is highly relevant here, because it highlights how much Legend is still investing to scale manufacturing, fund trials, and build beyond a single asset. How effectively the refreshed leadership team allocates that capital, particularly around CARVYKTI and early in vivo programs, now sits at the heart of both the upside case and the execution risk.

But investors should pay close attention to how quickly Legend can reduce its dependence on a single therapy before competitive pressures start to really…

Read the full narrative on Legend Biotech (it’s free!)

Legend Biotech’s narrative projects $2.2 billion revenue and $444.6 million earnings by 2029. This requires 24.4% yearly revenue growth and an earnings increase of about $695 million from -$250.1 million today.

Uncover how Legend Biotech’s forecasts yield a $54.23 fair value, a 185% upside to its current price.

Exploring Other Perspectives

Before this CEO exit, the most optimistic analysts were projecting Legend’s revenue to reach about US$2.7 billion and earnings of roughly US$869.2 million by 2029, a far more upbeat story than the concentration and competition risks I highlighted earlier. Your own view of this leadership change may tilt you closer to that bullish pipeline driven scenario or toward a more cautious stance that those forecasts now need to be revisited.

Explore 5 other fair value estimates on Legend Biotech – why the stock might be worth over 7x more than the current price!

Reach Your Own Conclusion

Don’t just follow the ticker – dig into the data and build a conviction that’s truly your own.

Want Some Alternatives?

The market won’t wait. These fast-moving stocks are hot now. Grab the list before they run:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include LEGN.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com